Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results

On February 27, 2023 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, reported its fourth quarter and full year 2022 financial results on Monday, March 6, 2023. The Company will host a conference call at 4:30pm ET on the same day (Press release, Cyclacel, FEB 27, 2023, View Source [SID1234627771]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call information:

Participant Toll-Free Number: 800-245-3047 Primary

Participant Direct/International Number: 203-518-9765 Alternate

Code for live and archived conference call is CYCCQ422. Webcast Link

For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for 7 days.

Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference

On February 27, 2023 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, reported that company management will participate in a corporate panel discussion and 1×1 investor meetings at the Cowen 43rd Annual Health Care Conference, which is taking place at the Boston Marriott Copley Place from March 6 – 8, 2023 (Press release, Cardiff Oncology, FEB 27, 2023, View Source [SID1234627770]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the panel discussion can be found below.

GI/GU Oncology Panel Discussion

Date:

Tuesday, March 7, 2023

Time:

Webcast Link:

12:50 PM ET

Here

A replay of the panel discussion will be available by visiting the "Events" section of the Cardiff Oncology website and will be archived for 30 days following the completion of the conference.

Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL Webinar

On February 27, 2023 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported that it will host a key opinion leader (KOL) webinar at 8 a.m. EST on Tuesday, February 28, 2023, to discuss the results from the recently completed pivotal Phase 3 SIERRA trial of Iomab-B, which were presented in a late-breaker presentation at the Transplantation & Cellular Therapy (TCT) tandem meetings on February 18, 2023 (Press release, Actinium Pharmaceuticals, FEB 27, 2023, View Source [SID1234627769]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sergio A. Giralt, MD, currently serves as Deputy Division Head, Division of Hematologic Malignances, the Melvin Berlin Family Chair in Multiple Myeloma and Chief Medical Officer, MSK Direct at Memorial Sloan Kettering Cancer Center and is a Professor of Medicine at Weil Cornell Medical College. Dr. Giralt will discuss the unmet medical needs of older patients with active Relapsed or Refractory Acute Myeloid Leukemia (r/r AML), along with the practice changing potential for Iomab-B in this patient population. The event will highlight the potential for Iomab-B, a first-in-class targeted radiotherapy, to improve access to potentially curative bone marrow transplants for these patients who are not considered viable for this procedure.

A live question and answer session will follow the formal presentations. To register for the event, please click here or visit the investor relations page of Actinium’s website here.

Sandesh Seth, Actinium’s Chairman and CEO, said, "We are honored that Dr. Giralt, who is instrumental in advancing the field of bone marrow transplant, will present the SIERRA data and frame how Iomab-B can address the unmet need for the majority of r/r AML patients who are not transplantable today. We are excited to move ahead with the BLA filing of Iomab-B in 2H:2023 following the highly positive, full results from the SIERRA trial which clearly established Iomab-B’s ability to provide unprecedented access to a BMT to patients who currently not transplantable and to meaningfully improve outcomes. Additionally, we are enthused by the other consequential milestones we intend to achieve in 2023 including moving Actimab-A into late-stage development following our recent CRADA with the NCI, additional data and important studies with Iomab-ACT, the Early Access Program for Iomab-B and progress with our earlier stage solid tumor programs. Our current balance sheet of approximately $100 million (unaudited) is expected to fund operations through 2025 and will allow us to continue to create value from these important milestones and provide clarity on how Actinium could radically alter the treatment of r/r AML with Iomab-B and Actimab-A and dramatically improve outcomes".

Sergio Giralt, MD, is a board-certified hematologist-oncologist, and his clinical activity and research focus is on stem cell transplantation for patients with blood disorders. He trained and worked for many years at the University of Texas M.D. Anderson Cancer Center, where he was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, Dr. Giralt joined the faculty of Memorial Sloan Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service and currently serves as Deputy Division Head, Division of Hematologic Malignances, the Melvin Berlin Family Chair in Multiple Myeloma and Chief Medical Officer, MSK Direct. He is an Attending Physician, Adult Bone Marrow Transplant Service at MSKCC and Professor of Medicine at Weil Cornell Medical College.

Dr. Giralt’s research focus has been on improving treatments for older patients who have acute and chronic leukemia. Along with his colleagues, he pioneered the use of reduced-intensity conditioning regimens for older or more debilitated patients with blood cancers which has changed the standard of care throughout the world. Dr. Giralt’s research interests span the continuum of transplant and cellular therapy and include T-cell depletion techniques to reduce the risk of graft-versus-host disease. He is a also a proponent of post-transplant maintenance therapies using a variety of targeted therapies, which they are continuing to explore at Memorial Sloan Kettering. Dr. Giralt recently chaired the executive board of the Center for International Blood and Marrow Transplant Research. He is also the past chair of the steering committee of the Blood and Marrow Transplant Clinical Trials Network, a federally funded group that defines the research agenda for stem cell transplantation in the United States.

To register for the event, please click here or visit the investor relations page of Actinium’s website here.

About Iomab-B and the Pivotal Phase 3 SIERRA Trial

Iomab-B is a first-in-class targeted radiotherapy intended to improve patient access to potentially curative BMT by simultaneously and rapidly depleting blood cancer, immune and bone marrow stem cells that uniquely express CD45. Multiple studies have demonstrated increased survival in patients receiving BMT, however, an overwhelming majority of patients with blood cancers do not receive BMT as current approaches do not produce a remission, which is needed to advance to BMT, or are too toxic. Studied in over 400 patients, prior studies with Iomab-B have demonstrated nearly universal access to BMT, increased survival and tolerability in multiple clinical trials including the recently completed pivotal Phase 3 SIERRA trial in patients with active (leukemic blasts >5%), relapsed or refractory acute myeloid leukemia (r/r AML) age 55 and above.

Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6 months after initial remission post-BMT in the pivotal Phase 3 SIERRA trial with high statistical significance (p<0.0001). Iomab-B produced a 75% post-BMT CR rate (44/59 patients), which is 12-times greater than the post-BMT rate of 6.3% (4/64 patients) in the control arm. Patients receiving Iomab-B had a 78% lower probability of an event, defined as not achieving a CR/CRp, crossover, not receiving a BMT, relapse or death, with a Hazard Ratio of 0.22 (p<0.0001). Iomab-B doubled 1-year overall survival with 26.1% compared to 13.1% in the control arm for patients who did not crossover as well as median overall survival with 6.4 months vs 3.2 months. Overall survival statistics are confounded by the crossover arm. Crossover patients had a 35.8% 1-year overall survival rate. Due to its targeted nature, Iomab-B was well tolerated with four times lower rates of sepsis compared to the control arm (6.1% vs. 28.6%) and lower rates of BMT associated adverse events including febrile neutropenia, mucositis and graft versus host disease (GVHD). Actinium intends to submit a Biologics License Application (BLA) seeking approval for Iomab-B in 2023 to address patients age 55+ with r/r AML who cannot access BMT with currently available therapies. Iomab-B has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and has patent protection into 2037.

The pivotal Phase 3 SIERRA (Study of Iomab-B in Elderly relapsed or refractory AML) is a 153-patient, randomized, multi-center clinical trial, studying Iomab-B compared to the control arm of physician’s choice of salvage therapy. Control arm options included chemotherapies like cytarabine and daunorubicin and targeted agents such as a Bcl-2 inhibitor (Venetoclax), FLT3 inhibitors and IDH 1/2 inhibitors. The SIERRA control arm reflects real-world treatment of r/r AML patients with over 20 agents used alone or in combination as no standard of care exists for this patient population. The SIERRA trial enrolled patients at 24 leading transplant centers in the United States and Canada that perform over 30% of AML BMTs.

Developed at the Fred Hutchinson Cancer Research Center, a pioneer in the field of BMT, Iomab-B is supported by data in six disease indications including leukemias, lymphomas and multiple myeloma, which afflict over 100,000 patients annually. Actinium intends to pursue additional indications for Iomab-B beyond AML. Actinium also intends to pursue international regulatory approvals independently and through partnerships. In April 2022, Actinium licensed the European, Middle East and North African commercial rights for Iomab-B to Immedica AB, a fully-fledged independent pharmaceutical company headquartered in Sweden. In exchange, Actinium received an upfront payment of $35 million USD with the potential for an additional $417 million USD in regulatory and sales milestones and mid-twenty percent royalties. Europe represents a commercial opportunity double the size of the United States by number of patients with AML receiving BMT. Iomab-B has been granted Orphan Drug Designation by the European Medicines Agency (EMA) and has received positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the EMA indicating that the Phase 3 SIERRA trial design, primary endpoint and planned statistical analysis are acceptable as the basis for a Marketing Authorization Application.

Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352

On February 27, 2023 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("AI") and machine learning ("ML") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported that it has entered into a research and development collaboration with TTC Oncology (Press release, Lantern Pharma, FEB 27, 2023, View Source [SID1234627768]). The collaboration will focus on leveraging RADR AI insights to advance TTC Oncology’s first- and best-in-class drug candidate TTC-352 for recurrent ER+ breast cancer patients and additional patient populations potentially identified by RADR. In US women, breast cancer remains the most commonly diagnosed cancer and second leading cause of cancer related deaths. ER+ breast cancers are estimated to account for 75-80% of all breast cancer cases and can have a recurrence rate between 13% and 41%. Globally, the treatment of ER+ breast cancer is estimated to have a $44 billion market potential by 2027.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"It is of the utmost importance for cancer drug development to understand targeted tumor biology and mechanisms of resistance in order to select the patient population that will benefit the most from novel therapy. We expect that by using Lantern’s RADR AI platform it can save us time and costs in the further successful clinical development of TTC-352 while providing important information for precision patient selection," said Dr. Arkadiusz Dudek, TTC Oncology Chief Medical Officer.

The collaboration will be powered by RADR’s 25+ billion oncology-focused data points, 200+ advanced ML algorithms, as well as its 4 multi-faceted AI drug discovery and development modules. The initial aims of the collaboration will be to 1) identify biomarker or gene signatures to power potential patient selection for an upcoming TTC-352 Phase 2 clinical trial, 2) further characterize TTC-352’s mechanism of action, and 3) discover additional treatment indications for TTC-352.

"Using AI insights generated by RADR, we are able to both sharpen existing clinical programs and uncover additional unrealized clinical potential of Lantern’s and our collaborators’ drug candidates," stated Panna Sharma, Lantern Pharma’s CEO and President. "We believe our AI-powered collaboration with TTC Oncology will accelerate the clinical development of TTC-352 for patients with metastatic ER+ breast cancer and will also identify new potential patient populations that can benefit from TTC-352 treatment," continued Sharma.

Under the terms of the collaboration, Lantern Pharma is receiving an exclusive right to license TTC-352, including any collaboration intellectual property (IP), during an exclusive option period. Additionally, Lantern and TTC will each participate in upfront, milestone, and royalty payments in the event a third party licenses IP resulting from the collaboration. No further financial details were disclosed.

About RADR

RADR is one of the world’s largest AI and ML oncology drug discovery and development platforms, consisting of over 25+ billion oncology-focused data points. These data points consist of large-scale multi-omic data, derived from 130,000+ patient records, 150+ drug-tumor interactions, thousands of drug classes, and covering over 135 cancer subtypes. RADR leverages this data and over 200+ advanced ML algorithms to power its drug discovery and development modules. RADR’s data, capabilities, and insights have powered the development of new Lantern drug candidates, advancement of new indications for existing drugs, and identification of new combinations at a fraction of the cost and time of traditional development approaches.

About TTC-352

TTC-352 is a novel, first-in-class and best-in-class orally available small molecule being developed as a treatment for patients with metastatic estrogen receptor-positive (ER+) breast cancer who have failed 2 or more prior therapies. TTC-352 is a selective human ER partial agonist (ShERPA) that induces unfolded protein response leading to breast cancer cell death, and acts in a similar manner as hormone therapy by modulating estrogen actions. In the US there are estimated to be around 290,000 cases of breast cancer annually, 80% of which are ER+.

TTC-352 was recently evaluated in a Phase 1 accelerated dose escalation study (NCT03201913) for hormone receptor positive metastatic breast cancer. A total of fifteen patients (n=15) were enrolled in the study and five escalating doses were evaluated. Despite the small cohort size, TTC-352 showed early efficacy signals in heavily pretreated hormone refractory patients (Median PFS was 58 days (95% CI = 28,112)) and showed a favorable safety profile. Additional published trial results can be found here.

About TTC Oncology

TTC Oncology is an emerging biotechnology company founded in 2015. TTC Oncology’s mission is to develop and bring to market a novel, small-molecule therapy, TTC-352, to address the unmet needs of breast cancer patients. TTC has a license from the University of Illinois at Chicago covering the therapy.

Entry into a Material Definitive Agreement

On February 27, 2023 Protalix BioTherapeutics, Inc., a Delaware corporation (the "Company") reported that it has entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC, as the Company’s sales agent (the "Agent") (Filing, 3 mnth, DEC 31, Protalix, 2022, FEB 27, 2023, View Source [SID1234627767]). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of the Company’s common stock having an aggregate offering price of up to $20,000,000 (the "Shares"). The Shares will be issued pursuant to the Company’s shelf registration statement on Form S-3 (Registration No. 333-264394). The Company intends to use the net proceeds from the offering, after deducting the Agent’s commissions and the Company’s offering expenses, for general corporate purposes, which may include but are not limited to working capital and funding clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Sales Agreement is in addition to the At The Market Offering Agreement the Company entered into with the Agent on July 2, 2021 and amended on May 2, 2022.

In accordance with the terms of the Sales Agreement, the Company may offer and sell the Shares at any time and from time to time through the Agent. Sales of the Shares, if any, will be made by means of transactions that are deemed to be "at the market" offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including block trades and sales made in ordinary brokers’ transactions on the NYSE American or otherwise at market prices prevailing at the time of the sale, at prices related to prevailing market prices or at negotiated prices. Under the terms of the Sales Agreement, the Company may also sell Shares to the Agent as principal for its own account at a price to be agreed upon at the time of sale. Any sale of Shares to the Agent as principal would be pursuant to the terms of a separate terms agreement between the Company and the Agent.

The foregoing description of the Sales Agreement in this report does not purport to be complete and is qualified by reference to the full text of the Sales Agreement, which is filed as Exhibit 1.1 hereto. The legal opinion and consent relating to the Shares are included as Exhibits 5.1 and 23.1, respectively, hereto.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any Shares, nor shall there be any sale of Shares in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.